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Abstract
The purpose of this study was to describe the patterns of antidiabetic medication use and the cost
of testing supplies in Canada using information collected by Saskatchewan's Drug Plan (DP) in 2001.
The diabetes cohort (n = 41,630) included individuals who met the National Diabetes Surveillance
System (NDSS) case definition. An algorithm was then used to identify subjects as having type 1 or
type 2 diabetes. Among those identified as having type 2 diabetes (n = 37,625), 38% did not have
records for antidiabetic medication in 2001. One-third of patients with type 2 diabetes received
monotherapy. Metformin, alone or in combination with other medications, was the most
commonly prescribed antidiabetic medication. Just over one-half of the all patients with diabetes
had a DP records for diabetes testing supplies. For individuals (n = 4,005) with type 1 diabetes, 79%
had a DP record for supplies, with an average annual cost of $472 ± $560. For type 2 diabetes, 50%
had records for testing supplies, with an average annual cost of $122 ± $233. Those individuals with
type 2 diabetes who used insulin had higher testing supply costs than those on oral antidiabetic
medication alone ($359 vs $131; p < 0.001).
Background
Diabetes affects approximately 5% of all Canadians aged
20 years or older, with the prevalence rising with age [1]
Type 2 diabetes accounts for 90% of the diagnosed cases
of diabetes in Canada, while approximately 10% of diabe-
tes cases are attributed to type 1 diabetes [1]. The National
Diabetes Surveillance System (NDSS) monitors epidemi-
ologic trends in diabetes in Canada and recently reported
on the prevalence of the disease and mortality in individ-
uals with diabetes [1]. It was estimated that approximately
5.2% of the non-First Nations Saskatchewan population
over the age of 20 had diabetes (4.9% of females and
5.5% of males) [1]. Both type 1 and type 2 diabetes can be
associated with a substantial burden for individuals with
the disease, their families and society as a whole.
The total costs of diabetes to health care systems have
been previously estimated for US and Canada [2,3] These
previous estimates have been modeled using data from
various sources. In order to better understand the magni-
tude of health care costs associated with the management
of diabetes, administrative health care data from Saskatch-
ewan have been used previously to estimate health care
costs of a cohort of 45,716 individuals identified as hav-
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ing diabetes during 1991 to 1996 [4,5]. Costs for hospital-
izations and day surgeries accounted for over 60% of
health care expenditures, with prescription expenditures
accounting for 20%, physician services accounting for
16%, and dialysis services accounting for 4% [4]. A large
proportion of health care expenditures for people with
diabetes is for macrovascular comorbidity [5]. We also
noted that in 1996, diabetes testing supplies accounted
for approximately 13% of the overall prescription expen-
ditures for people with diabetes [6].
Antidiabetic medications and diabetes testing supplies
play an important part in the management of diabetes,
but are associated with substantial and increasing costs for
provincial health care programs [4,5,7]. The current clini-
cal practice guidelines for the management of diabetes in
Canada were released in 2003 [8]. The guidelines provide
recommendations for self-monitoring of blood glucose,
and call for aggressive management (e.g., earlier initiation
of therapy) to avoid complications of diabetes. Despite
these guidelines, treatment gaps exist, whereby the actual
patterns of practice do not meet clinical practice guideline
recommendations. Treatment gaps for glycemic control
have been reported in Canada, although the patterns of
practice are often described for selected samples [9-11].
Harris' recent report on patterns of glycemic control in
Canada reflected practice patterns in a sample of patients
with type 2 diabetes from the primary care setting [10];
although it included patients from across the county, it
was based on a convenience sample and so may not be
reflective of the full population.
The purpose of this population-based study was to
describe the utilization of antidiabetic medications and
diabetes testing supplies within a provincial drug program
for individuals with diabetes. We were particularly inter-
ested in the population of type 2 diabetes and their pat-
terns of antidiabetic medication use and associated costs
of diabetes testing supplies during 2001.
Methods
Data sources and study population
Administrative databases from Saskatchewan Health that
contain information on prescription drug use, hospitali-
zations, and physician services for all eligible residents of
Saskatchewan were used in the analyses [12]. More than
99% of the province's population is covered by Saskatch-
ewan Health. Beneficiaries whose prescription drug bene-
fits are provided by a federal government agency (e.g.,
First Nations & Inuit Health, Health Canada) are not eli-
gible for Saskatchewan Health's prescription drug benefits
and therefore their prescriptions are not captured in the
prescription drug database. With these exclusions,
approximately 90% of the covered population are eligible
for prescription drug benefits [12].
Saskatchewan Health's administrative databases from
1991 to 2001 were used to identify non-registered Indian
prevalent and incident diabetes cases in the 2001 calendar
year. Using the NDSS criteria, [1] individuals were consid-
ered to have diabetes if they had two physician visits with
a diagnosis of diabetes (ICD-9 code of 250) on two differ-
ent days within any contiguous 730-day period or one
hospitalization with a discharge diagnosis of diabetes
(ICD-9 code of 250 from the first three diagnostic fields)
during the 11-year period [1]. The NDSS case definition is
typically applied for individuals 20 years and older; for
this report we have also included those less than 20 years
of age. From 1991 to 2001, 57,774 non-registered Indians
were identified as having diabetes. The 2001 cohort
included 41,630 diabetes cases (3108 incident and
38,522 prevalent cases). Approximately 16,144 diabetes
cases had exited the study by 2001 either due to death or
termination of Saskatchewan Health coverage.
Individuals were then categorized as type 1 or type 2 dia-
betes based on patterns of drug use. Individuals who were
on insulin only in 2001 and had no history of oral medi-
cation use were classified as having type 1 diabetes; all
others were considered to have type 2 diabetes.
The compiled study dataset included all prescriptions for
antidiabetic medications drugs and diabetes testing sup-
plies covered by the DP for all subjects identified with dia-
betes. The category for diabetes-related testing supplies
included in the data sets did not separate blood glucose
test strips and urine ketone testing agents; however, we
expect the majority of records are for blood glucose test
strips. Blood glucose meters, lancets, swabs, etc., were not
included in the diabetes-related testing supplies category.
Expenditures for diabetes testing supplies were compiled
from this administrative database. This dataset contains
the total approved and government portion of the cost.
This analysis was restricted to utilization during 2001 and
costs are therefore reported as 2001 Canadian dollars. The
research was approved by the Health Research Ethics
Board of the University of Alberta.
Data analysis
Descriptive statistics were used to characterize the cohorts
and patterns of antidiabetic medication and diabetes test-
ing supplies utilization for the 2001 calendar year. Total
costs of diabetes testing supplies were compared for type
1 and type 2 diabetes and among type 2 diabetes subjects
in four treatment groups, defined by DP records for pre-
scription medications: no DP records for any diabetes-
related medication, oral antidiabetic medication alone,
insulin alone or insulin in combination with oral antidia-
betic medications. As a proxy for disease duration in 2001,
subjects were also categorized according to quartiles of
duration of follow-up between 1991 and 2001 based onBMC Health Services Research 2006, 6:159 http://www.biomedcentral.com/1472-6963/6/159
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when they were identified as having diabetes: less than 3.0
years, 3.0 to 5.9 years, 6.0 to 9.9 years and 10.0 years or
greater. Patterns of medication use and total costs of dia-
betes testing supplies were then compared between type 1
and type 2 diabetes for each quartile of follow-up and
across quartiles within each type of diabetes. The nonpar-
ametric Kruskal-Wallis test was used for all comparisons.
Results
We identified 41,630 individuals with diabetes who were
eligible for prescription benefits and had not exited the
study due to death or coverage termination by 2001. The
majority (n = 37,625; 90%) of these were categorized as
having type 2 diabetes (Table 1). As would be expected,
subjects with type 2 diabetes were older than those with
type 1 diabetes (70.7 ± 16.2) versus 58.5 ± 22.1, p <
0.001). Subjects with type 1 and type 2 diabetes also dif-
fered with respect to duration of follow-up and location of
residence (Table 1).
Among those identified as having type 2 diabetes, approx-
imately one-third of patients received monotherapy. Met-
formin was the most commonly prescribed antidiabetic
drug, with almost one-quarter of pharmacologically
treated subjects receiving metformin monotherapy in
2001, and approximately 65% receiving metformin, alone
or in combination with other medications (Table 2).
Approximately 12% of all individuals with type 2 diabetes
received insulin in 2001 (Table 2). Over one-third of sub-
jects with type 2 diabetes (n = 14,157; 38%) did not have
records for antidiabetic medications in 2001, although
this varied substantially by duration of diabetes follow-up
(Figure 1). A clear pattern of increasing medication use
with longer duration of follow-up was apparent (Figure
1), with approximately 44% of individuals with 10 or
more years of follow-up receiving insulin therapy.
Just over one-half (53%) of the all patients with diabetes
had a DP record for diabetes testing supplies (Table 3).
For those individuals with type 1 diabetes, 79% (n =
3,143) had an DP record for diabetes testing supplies.
These individuals had a mean (standard deviation [SD])
of 5.8 (6.4) records in 2001, with a mean (SD) annual
total cost of $472 ($560). For all subjects identified with
type 2 diabetes, 50% (18,771) had records for testing sup-
plies (Table 3), with an overall mean (SD) of $122
($233). When considering the various therapies for indi-
viduals with type 2 diabetes, those managed with no anti-
diabetic medication had the lowest costs of testing
supplies (Table 3). Those individuals with type 2 diabetes
using insulin, alone or in combination with oral medica-
tion, had higher testing supply costs than those on oral
antidiabetic medication ($359 vs $131; p < 0.001).
Duration of follow-up in this sample was associated with
cost of diabetes testing supplies (Table 4). Interestingly,
however, the association was in different directions for
type 1 and type 2 diabetes. One-half of individuals identi-
fied with type 1 diabetes had follow-up for at least 10
years, but had the lowest cost of testing supplies during
2001 at $464, compared to $575 for those with type 1 dia-
betes for 3 years or less (Table 4). The cost of testing sup-
plies increased with duration in those identified with type
2 diabetes, from $107 for the shortest duration to $181
for those with type 2 diabetes for 10 years or more (Table
3).
Discussion
Our observations indicate that metformin was the most
commonly used antidiabetic medication in Saskatchewan
in 2001, used alone or in combination by two-thirds of
patients with type 2 diabetes who were treated with med-
ication. This pattern is consistent with the current CDA
guidelines, which recommend it as first line therapy for
most patients with diabetes [8]. Interestingly, however,
over one-third of patients with type 2 diabetes were not
dispensed antidiabetic medication in 2001, and were pre-
sumably managed by lifestyle (i.e., diet and exercise)
alone. While this may seem high at first glance, it is, in
fact, similar to estimates for other countries [13-15]. On
the other hand, Harris et al., in the recently reported Dia-
betes in Canada Evaluation (DICE) Study, only 15% of
Table 1: Diabetes Cohorts, Saskatchewan 2001
Type 1 Type 2
N (%) 4,005 (9.6%) 37,625 (90.4%)
Age*** – mean (SD), years 58.5 (22.1) 70.7 (16.2)
Sex – N (%), males 2,168 (54.1) 19,963 (53.1)
Residence*** – N (%), rural 1,734 (43.3) 17,469 (46.4)
Duration of follow-up*** – N (%)
Less than 3 years 421 (10.5) 10,040 (26.7)
3.0 to 6.0 years 458 (11.4) 9,004 (23.9)
6.0 to 10.0 years 1,115 (27.8) 10,509 (27.9)
10.0 or more years 2,011 (50.2) 8,072 (21.5)
*** p < 0.001BMC Health Services Research 2006, 6:159 http://www.biomedcentral.com/1472-6963/6/159
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patients with type 2 diabetes were managed by lifestyle
alone, although this varied widely depending on the dura-
tion of diabetes [10]. In our data, 46% of individuals with
type 2 diabetes had no records for drug therapies made
during the first 3 years after identification of their diabe-
tes.
We were limited in this analysis to administrative records,
making it difficult to determine the appropriateness of the
observed patterns of medication use relative to actual gly-
cemic control or other clinical characteristics (e.g., BMI).
A number of previous reports in Canada and elsewhere
have indicated that treatment gaps exist, with suboptimal
management of glycemic control in people with type 2
diabetes [9-11,16]. We suspect that our population would
have similar characteristics to those previous reports of
Canadian populations. For example, Harris et al., in the
recent DICE Study, found that while the mean A1c was
7.3%, about one-half of subjects with type 2 diabetes were
not at target (i.e., A1c < 7.0%) [10]. Similarly, Toth et al.
found that the average A1c among a sample of people
with type 2 diabetes in northern Alberta was 7.3%, but
50% of subjects were not at target [9]. Furthermore, the
majority of subjects not at target A1c were on single or no
antidiabetic medication [9].
The current clinical practice guidelines for diabetes man-
agement in Canada call for more aggressive management
for people with diabetes, including glycemic control [8]. It
should be noted that all of the previous evaluations were
undertaken prior to the wide dissemination of the recent
CPG, which were released in December 2003. Given the
typically slow rate of adoption of new evidence into prac-
tice, we suspect that patterns of practice have improved
since 2001, but not substantially so. The discordance
between recommendations and actual practice can be par-
tially attributed to "clinical inertia," which has been
defined as the recognition of a problem with a patient's
management but a failure to act [16]. Shah et al. recently
showed that clinical inertia is common for diabetes,
regardless of whether a diabetes specialist has been
involved in patient care[16]. Perhaps even more concern-
ing, given that macrovascular disease is the leading cause
of death in this population, is the evidence of even greater
treatment gaps for management of cardiovascular risk
[17,18].
We also highlight the costs associated with diabetes self-
testing in Saskatchewan in 2001. As would be expected,
individuals with type 1 diabetes, followed by those with
type 2 diabetes on insulin, had the highest expenditures
Table 2: Utilization of Diabetes Medication for Type 2 diabetes, Saskatchewan 2001
Therapy Number of Patients with Type 
2 Diabetes
% of Total Patients with Type 
2 Diabetes (n = 37625)
% of Type 2 Diabetes Patients 
Receiving Antidiabetic 
Therapy (n = 23,468)
Monotherapy 12814 34.1 54.6
SU 4803 12.8 20.5
Met 5767 15.3 24.6
TZD 32 0.1 0.1
Insulin 2212 5.9 9.4
Oral Combination Therapy 7493 19.9 31.9
SFU+Met 6764 18.0 28.8
SFU+TZD 59 0.2 0.3
Met+TZD 137 0.4 0.6
SFU+Met+TZD 533 1.4 2.3
Oral + Insulin Combination 2151 5.7 9.2
SFU+Ins 142 0.4 0.6
Met+Ins 1202 3.2 5.1
TZD+Ins 53 0.1 0.2
SFU+Met+Ins 554 1.5 2.4
SFU+TZD+Ins 15 0.0 0.1
Met+TZD+Ins 88 0.2 0.4
SFU+Met+TZD+Ins 97 0.3 0.4
Other Antidiabetic Drugs 1010 2.7 4.3
No diabetes drugs 14157 37.6 -
Total 37625 100 100BMC Health Services Research 2006, 6:159 http://www.biomedcentral.com/1472-6963/6/159
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for diabetes testing supplies. Interestingly, however, over-
all only one-half of subjects identified with diabetes had
records for diabetes testing supplies. This was an increase
over our previous report, where only 43% of diabetic sub-
jects in Saskatchewan in 1996 had DP records for testing
supplies [6]. The increase appears to be primarily in sub-
jects with type 2 diabetes managed with oral medications,
from 49% in 1996 to 63% in 2001 [6].
Table 3: Utilization and cost of diabetes testing supplies by Type of Diabetes and Treatment, Saskatchewan 2001
Number of Cases Number (%) of 
Subjects with ≥ 1 
record for testing 
supplies
Average (SD) 
Number of 
Records
Average (SD) DP 
share (Can$)
Average (SD) 
Patient Share 
(Can$)
Average (SD)A, B 
Total (Can$)
Type 1 4005 3143 (78.5) 5.8 (6.4) 231.71 (408.53)A 240.60 (343.81)A 472.31 (560.75)A
(% of Total) (9.6%) (49.1%) (50.9%)
Type 2
No medication 14157 3169 (22.4%) 0.5 (1.5) 11.78 (62.14)B 23.69 (72.61)B 35.47 (107.22)B
(% of Type 2) (37.6%) (33.2%) (66.8%)
Oral anti-diabetic 
agent only
18910 11814 (62.5) 2.0 (2.6) 57.78 (132.42) 73.42 (110.65) 131.21 (189.78)
(% of Type 2) (50.3%) (44.0%) (56.0%)
Insulin only 2212 1751 (79.2) 4.6 (5.0) 194.53 (296.40) 153.33 (233.26) 347.86 (409.39)
(% of Type 2) (5.9%) (55.9%) (44.1%)
Insulin and oral 
anti-diabetic agent
2346 2037 (86.8) 4.9 (4.4) 220.08 (286.55) 148.48 (187.50) 368.56 (362.67)
(% of Type 2) (6.2%) (59.7%) (40.3%)
Type 2 Total 37625 18771 (49.9) 1.8 (2.9) 58.63 (155.18)A 64.09 (122.86)A 122.72 (233.88)A
(% of Total) (90.4%) (47.8%) (52.2%)
A p < 0.001 between type 1 and type 2 diabetes using the Kruskal Wallis Test
B p < 0.001 between treatment groups within type 2 diabetes (i.e. no medication, oral anti-diabetic agent only, insulin only, insulin and oral anti-
diabetic agent) using the Kruskal Wallis Test
Antidiabetic Medication use in Type 2 diabetes in 2001 by Duration of Follow-up Figure 1
Antidiabetic Medication use in Type 2 diabetes in 2001 by Duration of Follow-up.
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Self-monitoring of blood glucose (SMBG) is considered a
cornerstone of self-management for all people with diabe-
tes [8,19]. There are, however, no specific guidelines on
testing frequency, particularly for people with type 2 dia-
betes. Indeed, the precise role and benefits of SMBG in
patients with type 2 diabetes is unclear. While there
appears to be some benefit of testing for those on insulin
to avoid hypoglycemia [20], the little evidence associating
SMBG with better glycemic control in patients not on
insulin is weak and conflicting [20-23]. The lack of good
evidence has prompted some opinion leaders to suggest
that SMBG for people with type 2 diabetes not receiving
insulin is a "waste of money"[24]. Two-thirds of the total
cost of diabetes testing supplies in Saskatchewan in 2001
were incurred for individuals with type 2 diabetes, and
approximately 80% of the individuals with type 2 diabe-
tes who had records for diabetes testing supplies were
managed by lifestyle alone or were on oral medications
only. As provincial health systems provide insurance cov-
erage for diabetes testing supplies, studies into the clinical
and economic impact of this policy should be considered.
Our estimates for drug and testing supply use should be
considered in light of several limitations. First, while there
is good evidence of validity of the NDSS criteria for iden-
tifying diabetes cases, some cases may still be missed [25].
Individuals whose physicians do not use fee-for-service
billing, for example, may not meet the NDSS criteria for
diabetes unless they are hospitalized for diabetes. In Sas-
katchewan's northern health districts, some physicians
were under salary during the study period and did not bill
for their services under the fee-for-service structure [4].
Furthermore, the NDSS criteria have only been validated
in adults over the age of 20; we applied the same criteria
to identify diabetes in all age groups. The result of both of
these limitations is an underestimation of the prevalence
of diabetes, and therefore utilization and cost of services.
In addition, our approach to identifying individuals with
type 1 or type 2 diabetes has not been validated against
chart audits. Nonetheless, by considering the patterns of
medication use, we identified the majority of people
(90%) as having type 2 diabetes, which is what would be
expected with the known epidemiology of diabetes [1].
Finally, our utilization and cost estimates are derived from
2001 data, and may not reflect more contemporary pat-
terns of utilization and cost.
Conclusion
In Saskatchewan in 2001, metformin, alone or in combi-
nation, was the most frequently dispensed oral antidia-
betic medication. A longer history of diabetes was
associated with increased use of oral medications and
insulin therapy. Insulin was used in approximately 12%
of patients with type 2 diabetes and was associated with
approximately three times higher expenditure on diabetes
testing supplies compared to patients on oral anti-diabetic
medications. Individuals with type 1 diabetes had the
highest expenditures for testing supplies.
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